Antiangiogenics: new therapeutic standards in metastatic kidney cancer

Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
J-N CornuJ-J Patard

Abstract

Since 2004, the treatment of metastatic renal cell carcinoma is in deep mutation. Before, the Management was mostly relying on the use of cytokines in association with radical nephrectomy. From 2004, studies of new antiangiogenic molecules, acting on the pVHL-HIF way, VEGF, PDGF or tyrosine-kinase receptors have modified the management of metastatic patients. Antiangiogenic agents improve progression-free survival as shown with sunitinib, in first line treatment, or sorafenib, as second line treatment. The m-TOR inhibitors (Temsirolimus), can be used with a benefit on overall survival in case of poor prognosis renal cell carcinoma or non clear cell carcinoma. Lastly, bevacizumab, an antibody re-combining humanized monoclonal, is able to target VEGF. Side effects are different for each molecule and are not negligible. Nevertheless, the place of these molecules have to be defined in the sequence of the treatment.

References

Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsMatthew L Sherman
May 12, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric RaymondJean-Pierre Armand
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald M BukowskiDavid McDermott

❮ Previous
Next ❯

Citations

Apr 2, 2013·World Journal of Urology·Pierre BigotJean-Christophe Bernhard
Mar 16, 2011·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·Y Neuzillet, C Delbado
Oct 16, 2009·Expert Review of Anticancer Therapy·Axel S MerseburgerMarkus A Kuczyk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
F Radvanyi
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
A Méjean, T Lebret
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
A Méjean, T Lebret
© 2022 Meta ULC. All rights reserved